These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31500395)

  • 1. Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules.
    Delport A; Hewer R
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31500395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted protein degradation: A promise for undruggable proteins.
    Samarasinghe KTG; Crews CM
    Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy.
    Ottis P; Crews CM
    ACS Chem Biol; 2017 Apr; 12(4):892-898. PubMed ID: 28263557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.
    Buckley DL; Raina K; Darricarrere N; Hines J; Gustafson JL; Smith IE; Miah AH; Harling JD; Crews CM
    ACS Chem Biol; 2015 Aug; 10(8):1831-7. PubMed ID: 26070106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted protein knockdown using small molecule degraders.
    Raina K; Crews CM
    Curr Opin Chem Biol; 2017 Aug; 39():46-53. PubMed ID: 28605671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTACs to address the challenges facing small molecule inhibitors.
    Martín-Acosta P; Xiao X
    Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.
    Buckley DL; Crews CM
    Angew Chem Int Ed Engl; 2014 Feb; 53(9):2312-30. PubMed ID: 24459094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.
    Yang Y; Wu Z; Chen P; Zheng P; Zhang H; Zhou J
    Future Med Chem; 2020 Sep; 12(18):1669-1683. PubMed ID: 32893690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein degradation: a validated therapeutic strategy with exciting prospects.
    Lebraud H; Heightman TD
    Essays Biochem; 2017 Nov; 61(5):517-527. PubMed ID: 28970340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging mechanisms of targeted protein degradation by molecular glues.
    Frere GA; de Araujo ED; Gunning PT
    Methods Cell Biol; 2022; 169():1-26. PubMed ID: 35623698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reimagining Druggability Using Chemoproteomic Platforms.
    Spradlin JN; Zhang E; Nomura DK
    Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted protein degradation: current and future challenges.
    Hanzl A; Winter GE
    Curr Opin Chem Biol; 2020 Jun; 56():35-41. PubMed ID: 31901786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands.
    Han B
    J Biol Chem; 2020 Nov; 295(45):15280-15291. PubMed ID: 32859748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.
    Foley CA; Potjewyd F; Lamb KN; James LI; Frye SV
    ACS Chem Biol; 2020 Jan; 15(1):290-295. PubMed ID: 31846298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein degradation technology: a strategic paradigm shift in drug discovery.
    Li H; Dong J; Cai M; Xu Z; Cheng XD; Qin JJ
    J Hematol Oncol; 2021 Sep; 14(1):138. PubMed ID: 34488823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins.
    Ohoka N; Tsuji G; Shoda T; Fujisato T; Kurihara M; Demizu Y; Naito M
    ACS Chem Biol; 2019 Dec; 14(12):2822-2832. PubMed ID: 31580635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.